September 26, 2016 12:46 PM ET

Biotechnology

Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...

3033 Science Park Road

Suite 300

San Diego, CA 92121

United States

Founded in 2008

68 Employees

Phone:

858-652-5700

Fax:

858-587-2659

Key Executives for Receptos, Inc.

Scientific Founder and Member of Scientific Advisory Board
Age: 57
Chief Financial Officer
Age: 60
Managing Director
Age: 49
Compensation as of Fiscal Year 2016.

Receptos, Inc. Key Developments

Receptos, Inc. Announces Executive Changes

Receptos, Inc. entered into an agreement and plan of merger with Celgene Corporation. In accordance with the terms of the Merger Agreement, as of the effective time, each of William H. Rastetter, Ph. D., Kristina Burow, Mary Lynne Hedley, Ph. D., Richard A. Heyman, Ph. D., Erle T. Mast, Mary Szela, S. Edward Torres and Faheem Hasnain ceased serving as directors of the company, and the directors of Purchaser at the Effective Time became the directors of the Surviving Corporation. Additionally, in accordance with the terms of the Merger Agreement, as of the Effective Time, each of Faheem Hasnain, Graham Cooper, Sheila K. Gujrathi, M.D., Marcus F. Boehm, Ph.D. and Robert Peach, Ph.D. ceased serving as officers of the Company.

Receptos, Inc.(NasdaqGS:RCPT) dropped from NASDAQ Composite Index

Receptos, Inc. will be removed from Nasdaq Composite Index.

Receptos, Inc.(NasdaqGM:RCPT) dropped from Russell Global Index

Receptos, Inc.(NasdaqGM:RCPT) dropped from Russell Global Index

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Receptos, Inc., please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.